Abstract
Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 185-204 |
Number of pages | 20 |
Journal | Expert Review of Ophthalmology |
Volume | 9 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2014 |
Externally published | Yes |
Keywords
- BRAF inhibitors
- Conjunctival malignant melanoma
- Dabrafenib
- IFNa-2b
- Ipilimumab
- Melanoma mitomycin C
- Ocular neoplasm
- Vemurafenib
ASJC Scopus subject areas
- Biomedical Engineering
- Ophthalmology
- Optometry